ChromaDex Corp. announced that it has entered into a material transfer agreement (MTA with Murdoch Childrens Research Institute, the preeminent child

ChromaDex Corp. announced the financial results for the quarter ended June 28, 2014.

ChromaDex Corp. announced the initiation of the second human clinical study for PURENERGY, its patented caffeine ingredient.